TargetBeta
EPHB2
EPH receptor B2 · also Hek5, Tyro5, DRT, ERK · Sterile alpha motif domain containing
1 program in company-led studies act on EPHB2, from 1 company: 1 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (1 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| olverembatinibrule | Ascentage Pharma Group International | phase 3 | 105 running | ABL1, BCR | NCIt |
Conditions their studies are in
- Gastrointestinal Stromal Tumors, 1 program
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive, 1 program
- Leukemia, Myeloid, Accelerated Phase, 1 program
- Leukemia, Myeloid, Chronic-Phase, 1 program
- Precursor Cell Lymphoblastic Leukemia-Lymphoma, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Mar 31, 2027olverembatinib · Ascentage Pharma Group International · phase 3 · NCT06640361
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.